PTE - PolarityTE, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.7000
+0.1100 (+2.40%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close 4.5900
Open 4.6000
Bid 4.7200 x 1800
Ask 4.7200 x 2200
Day's Range 4.6000 - 4.8400
52 Week Range 3.8400 - 30.8800
Volume 253,949
Avg. Volume 314,031
Market Cap 118.007M
Beta (3Y Monthly) 1.64
PE Ratio (TTM) N/A
EPS (TTM) N/A
Earnings Date N/A
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date 2016-01-12
1y Target Est N/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • PolarityTE to Present at Military Health System Research Symposium on Platform Technology for Treatment of Traumatic and Chronic Wounds
    PR Newswire

    PolarityTE to Present at Military Health System Research Symposium on Platform Technology for Treatment of Traumatic and Chronic Wounds

    SALT LAKE CITY, Aug. 16, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will present data on the potential for SkinTE™ and OsteoTE™ to address military-related traumas and chronic wounds at the Military Health System Research Symposium on August 21, 2019, in Kissimmee, FL. SkinTE is a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for the repair, reconstruction and replacement of a patient's own skin. OsteoTE, based on the same platform technology, is an autologous, homologous human cellular and tissue-based product intended to repair, reconstruct, replace and supplement bone.

  • PolarityTE Reports Second Calendar Quarter 2019 Results
    PR Newswire

    PolarityTE Reports Second Calendar Quarter 2019 Results

    SALT LAKE CITY , Aug. 8, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today reported financial ...

  • PolarityTE to Report Calendar Second Quarter Financial Results on August 8, 2019
    PR Newswire

    PolarityTE to Report Calendar Second Quarter Financial Results on August 8, 2019

    SALT LAKE CITY, July 25, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will report its calendar second quarter 2019 financial results by press release on Thursday, August 8, 2019 at approximately 7:00 a.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on Thursday, August 8, 2019 at 8:00 a.m. Eastern Time. The conference call can be accessed by calling 1-888-394-8218 (U.S. and Canada) or +44 (0)330 336 9105 (International), with confirmation code 1393700 and referencing "PolarityTE Second Quarter 2019 Earnings Call".  A webcast of the conference call can be accessed by using the link below.

  • PolarityTE Announces Final Clinical Data from Pilot Study Showing Closure of Diabetic Foot Ulcers Using SkinTE
    PR Newswire

    PolarityTE Announces Final Clinical Data from Pilot Study Showing Closure of Diabetic Foot Ulcers Using SkinTE

    SALT LAKE CITY, June 10, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today the final results from a pilot study on the use of its SkinTE™ product for hard-to-treat diabetic foot ulcers (DFUs). The data was presented at the American Diabetes Association's 79th Scientific Sessions conference. SkinTE is a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for the repair, reconstruction and replacement of a patient's own skin.

  • PolarityTE Creates Office of the Chief Executive to Focus on Commercialization and Operational Performance
    PR Newswire

    PolarityTE Creates Office of the Chief Executive to Focus on Commercialization and Operational Performance

    SALT LAKE CITY, June 3, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE) today announced that the Board of Directors has created the Office of the Chief Executive, consisting of a team of three senior executives who will focus and collaborate on commercialization, operational and financial performance, and new product development. Members of the Office of the Chief Executive include Richard Hague, Chief Operating Officer, Paul Mann, Chief Financial Officer and David Seaburg, President of Corporate Development.  Dr. Denver Lough remains the Chairman of the Board and is on indefinite administrative leave from the offices of Chief Executive Officer and Chief Research & Development Officer.

  • Final Data from Pilot Study on Use of SkinTE for Diabetic Foot Ulcers Accepted as Late-Breaking Abstract at the American Diabetes Association's 79th Scientific Sessions Conference
    PR Newswire

    Final Data from Pilot Study on Use of SkinTE for Diabetic Foot Ulcers Accepted as Late-Breaking Abstract at the American Diabetes Association's 79th Scientific Sessions Conference

    SALT LAKE CITY, May 21, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that final data from a pilot study on the use of its SkinTE™ product for hard-to-treat diabetic foot ulcers (DFUs), will be presented at the American Diabetes Association's 79th Scientific Sessions conference at the Moscone Center in San Francisco, California. SkinTE is a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for the repair, reconstruction and replacement of a patient's own skin. The poster, Results of a Pilot Evaluation of a Novel Autologous Homologous Skin Construct Treatment of Diabetic Foot Wounds Refractory to Conventional Treatments (#45-LB), will be presented on Sunday, June 9, 2019 from 12:00 PM – 1:00 PM by David G. Armstrong, MD, PhD, DPM, Professor of Clinical Surgery at the Keck School of Medicine at the University of Southern California and co-Director of the Southwestern Academic Limb Salvage Alliance.

  • PolarityTE Announces Clinical Data from Two Studies Showing 12-Week Closure of Difficult-to-Treat Lower Extremity Chronic Wounds Using SkinTE
    PR Newswire

    PolarityTE Announces Clinical Data from Two Studies Showing 12-Week Closure of Difficult-to-Treat Lower Extremity Chronic Wounds Using SkinTE

    SALT LAKE CITY, May 10, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today data from two pilot studies on the use of its SkinTE™ product both showing successful closure of diabetic foot ulcers (DFUs) and venous stasis leg ulcers (VLUs) within a 12-week period. The cases involved patients with lower extremity chronic wounds that were difficult to treat or had failed to heal with standard dressing care and conventional treatments, using a single application of SkinTE. The data from each of the clinical case series was presented yesterday at the Symposium on Advanced Wound Care (SAWC) spring conference in San Antonio, TX.

  • PolarityTE Reports First Calendar Quarter 2019 Results
    PR Newswire

    PolarityTE Reports First Calendar Quarter 2019 Results

    SALT LAKE CITY , May 10, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today reported financial ...

  • PolarityTE to Report Calendar First Quarter Financial Results on May 10, 2019
    PR Newswire

    PolarityTE to Report Calendar First Quarter Financial Results on May 10, 2019

    SALT LAKE CITY, May 1, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will report its calendar first quarter 2019 financial results by press release on May 10, 2019 at approximately 7:00 a.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on Friday, May 10, 2019 at 8:00 a.m. Eastern Time. The conference call can be accessed by calling 1-800-289-0438 (U.S. and Canada) or +44 (0)330 336 9105 (International), with confirmation code 3828997 and referencing "PolarityTE First Quarter 2019 Earnings Call."  A webcast of the conference call can be accessed by using the link below.

  • SkinTE Clinical Data to be Presented, PolarityTE to Host Booth and SkinTE Event at Symposium on Advanced Wound Care (SAWC) Spring, Wound Healing Society Meeting
    PR Newswire

    SkinTE Clinical Data to be Presented, PolarityTE to Host Booth and SkinTE Event at Symposium on Advanced Wound Care (SAWC) Spring, Wound Healing Society Meeting

    SALT LAKE CITY, April 24, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that new clinical data on the use of its SkinTE™ product will be presented at the Symposium on Advanced Wound Care (SAWC) Spring, Wound Healing Society meeting in San Antonio, TX from May 7 – 11, 2019. In addition, PolarityTE will host a booth and an interactive event featuring patients treated with SkinTE and a presentation from Dr. Gerhard S. Mundinger, MD, Division of Plastic Surgery, Louisiana State University Health Sciences Center, an early adopter of SkinTE, on his clinical experience with the product.

  • PolarityTE Announces Pricing of Public Offering of Common Stock
    PR Newswire

    PolarityTE Announces Pricing of Public Offering of Common Stock

    SALT LAKE CITY, April 10, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, announced today the pricing of an underwritten public offering of approximately $27.5 million of shares of its common stock. In addition, PolarityTE has granted the underwriter a 30-day option to purchase up to $4,125,000 of additional shares of its common stock. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.

  • PolarityTE Announces Public Offering of Common Stock
    PR Newswire

    PolarityTE Announces Public Offering of Common Stock

    SALT LAKE CITY, April 9, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, announced today that it has commenced an underwritten public offering of shares of its common stock. In addition, PolarityTE intends to grant the underwriters for the offering a 30-day option to purchase up to an additional 15% of the shares of its common stock at the price to the public, less underwriting discounts and commissions. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.

  • PR Newswire

    Lifshitz & Miller LLP Announces Investigation of Bloom Energy Corporation, First Choice Healthcare Solutions, Inc., Nutanix, Inc., PolarityTE, Inc., Revlon, Inc., Tivity Health, Inc., WellCare Health Plans, Inc., and Whitestone REIT

    NEW YORK , April 2, 2019 /PRNewswire/ -- Bloom Energy Corporation (BE) Lifshitz & Miller   announces investigation into possible securities laws violations in connection with BE's IPO at $15.00 per share. ...

  • PolarityTE Enrolls First Patients in Two Clinical Trials Evaluating SkinTE for the Treatment of Chronic Wounds
    PR Newswire

    PolarityTE Enrolls First Patients in Two Clinical Trials Evaluating SkinTE for the Treatment of Chronic Wounds

    SALT LAKE CITY, April 1, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that patient enrollment has begun for two new randomized controlled trials evaluating SkinTE™ for the treatment of chronic wounds, specifically diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). SkinTE is commercially available through a regional market release and is a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for skin repair, reconstruction and replacement. The Company's two randomized controlled trials will be led by the principal investigator David G. Armstrong, DPM, MD, PhD, Professor of Surgery at the University of Southern California, founder of the Southwestern Academic Limb Salvage Alliance, and a world expert in wound healing and limb preservation.

  • PolarityTE Announces Richard Hague, Formerly from Sanofi, Genzyme and Recently Anika Therapeutics as Chief Operating Officer
    PR Newswire

    PolarityTE Announces Richard Hague, Formerly from Sanofi, Genzyme and Recently Anika Therapeutics as Chief Operating Officer

    SALT LAKE CITY, March 29, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that Richard Hague will join as the Company's Chief Operating Officer on April 8, 2019. Mr. Hague brings to PolarityTE experience in many aspects of corporate development and operations from his more than 30-year career in the biotechnology industry, including launching a variety of autologous cell and tissue therapies. Current COO Ned Swanson, MD, will continue on as PolarityTE's Chief Translational Medicine Officer.

  • Clinical Outcomes Data on SkinTE™ from Lower Extremity Chronic Wounds to be Presented at Diabetic Limb Salvage (DLS) Conference
    PR Newswire

    Clinical Outcomes Data on SkinTE™ from Lower Extremity Chronic Wounds to be Presented at Diabetic Limb Salvage (DLS) Conference

    SALT LAKE CITY, March 27, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that two clinical outcomes abstracts on SkinTE™ for the treatment of diabetic foot ulcers (DFUs) will be presented at the Diabetic Limb Salvage (DLS) Conference in Washington, DC being held on April 4-6, 2019. SkinTE is a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for the repair, reconstruction and replacement of patient's own skin. One of the abstracts, which includes data from the pilot study for a randomized controlled trial evaluating SkinTE for DFUs, has been recognized with a Top Abstract Special Designation.

  • PolarityTE Hosts Symposium Featuring SkinTE-Treated Burn Survivor, New Clinical Data at American Burn Association Annual Meeting
    PR Newswire

    PolarityTE Hosts Symposium Featuring SkinTE-Treated Burn Survivor, New Clinical Data at American Burn Association Annual Meeting

    SALT LAKE CITY, March 21, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today it will host a symposium at the American Burn Association (ABA) 51st Annual Meeting featuring a burn survivor who will share her story after being treated with the Company's SkinTE™ product. The Company's symposium is Wednesday, April 3, from 7-8:30 p.m. SkinTE is a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for skin repair, reconstruction and replacement.

  • PolarityTE to Present at Oppenheimer 29th Annual Healthcare Conference
    PR Newswire

    PolarityTE to Present at Oppenheimer 29th Annual Healthcare Conference

    SALT LAKE CITY , March 19, 2019 /PRNewswire/ --  PolarityTE, Inc. (Nasdaq: PTE)   announced today that it will attend and present at the Oppenheimer 29 th Annual Healthcare Conference on March 20, 2019 ...

  • RM LAW Announces Investigation of PolarityTE, Inc.
    PR Newswire

    RM LAW Announces Investigation of PolarityTE, Inc.

    BERWYN, Pa. , March 19, 2019 /PRNewswire/ --  RM LAW, P.C. announces an investigation on behalf of PolarityTE, Inc. (NASDAQ: PTE) ("PolarityTE" or the "Company") investors concerning ...

  • Business Wire

    Federman & Sherwood Investigates PolarityTE, Inc. for Possible Violations of Federal Securities Laws

    The law firm of Federman & Sherwood has initiated an investigation into PolarityTE, Inc. (PTE) with respect to possible violations of federal securities laws. PTE, Inc. is headquartered in Salt Lake City, Utah. On March 18, 2019, PTE disclosed that “[o]n March 4, 2019, we obtained from the SEC a copy of the formal order of investigation of the Company and its affiliates with respect to possible violations of the federal securities laws, including, among other things, the anti-fraud provisions of the Securities Act and the Exchange Act with respect to the Company’s public disclosures, the beneficial ownership reporting provisions of the Exchange Act and the anti-price manipulation provisions of the Exchange Act.” On this news, shares of PTE fell $2.42 per share, or over 15%, to close at $13.05 per share on March 18, 2019, damaging investors.

  • GlobeNewswire

    PolarityTE (PTE) Investigation: Bernstein Liebhard LLP Announces Investigation of PolarityTE, Inc. - PTE

    Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of PolarityTE, Inc. (“PolarityTE” or the “Company”) (PTE) resulting from allegations that PolarityTE and/or its executives may have issued materially misleading business information to the investing public. If you purchased PolarityTE securities, and/or would like to discuss your legal rights and options, please visit PolarityTE Shareholder Investigation or contact Daniel Sadeh toll free at (877) 779-1414 or dsadeh@bernlieb.com.

  • GlobeNewswire

    Bragar Eagel & Squire, P.C. is Investigating PolarityTE, Inc. (PTE) on Behalf of Stockholders and Encourages PTE Investors to Contact the Firm

    NEW YORK, March 18, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against PolarityTE, Inc. (NASDAQ: PTE). Our investigation concerns whether.

  • PolarityTE (PTE) Investigation: Bernstein Liebhard LLP Announces Investigation Of PolarityTE, Inc. - PTE
    PR Newswire

    PolarityTE (PTE) Investigation: Bernstein Liebhard LLP Announces Investigation Of PolarityTE, Inc. - PTE

    NEW YORK , March 18, 2019 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of PolarityTE, ...

  • PolarityTE Reports Results and Corporate Update for Two-Month Transition Period Ended December 31, 2018
    PR Newswire

    PolarityTE Reports Results and Corporate Update for Two-Month Transition Period Ended December 31, 2018

    SALT LAKE CITY , March 18, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, ...

  • PolarityTE to Attend Medlab Asia Pacific and Asia Health 2019 Conferences
    PR Newswire

    PolarityTE to Attend Medlab Asia Pacific and Asia Health 2019 Conferences

    SALT LAKE CITY, March 13, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE) announced today that it will attend the Medlab Asia Pacific and Asia Health 2019 conferences in Singapore from March 26-28, 2019. PolarityTE is a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. PolarityTE is a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences.